Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19195169 | 1.00 | NFE2L2 (0.33) | NFE2L2PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL19196400 | 0.86 | PDE4A (0.36) | NFE2L2PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL19195306 | 0.86 | PDE4A (0.36) | NFE2L2PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL19196408 | 0.81 | ADORA2B (0.31) | NFE2L2ADORA2B | |
| SCHEMBL19195389 | 0.81 | NFE2L2 (0.31) | NFE2L2 | |
| SCHEMBL19195402 | 0.81 | NFE2L2 (0.31) | NFE2L2 | |
| SCHEMBL19195396 | 0.81 | ADORA2B (0.31) | NFE2L2ADORA2B | |
| SCHEMBL19195550 | 0.80 | PDE4A (0.35) | NFE2L2PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL19195390 | 0.80 | PDE4A (0.35) | NFE2L2PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL19196409 | 0.78 | NFE2L2 (0.32) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845307-B2 | Nrf2 activating compounds and uses thereof | MIDCAP FINANCIAL TRUST | 2017-12-19 | — | — | US | disclosed |
| US-20170217922-A1 | Nrf2 Activating Compounds and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217922-A1 | Nrf2 Activating Compounds and Uses Thereof | NFE2L2, KEAP1, NQO1 | NFE2L2 1/4885PDE4A 984/4885ADORA2A 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.